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HIV-1 entry into cells requires the interaction of both HIV-1 envelope proteins and membrane lipids.
We investigated the mechanism of neutralization of HIV-1 infection of primary monocyte-derived
macrophages (MDM) by a murine monoclonal antibody (mAb) WR321. WR321 speciﬁcally binds
phosphatidylinositol-4-phosphate and phosphatidylinositol-4,5-bisphosphate. These phosphoinosi-
tides are present not only on the inner surface of the plasma membranes of cells but also on the
surface of virions. HIV-1 acquires these lipids during the budding process. Pre-incubation of WR321
with the virus but not with MDM neutralized HIV-1 infection of MDM. Our results demonstrate that
WR321 was internalized only when it was bound to HIV-1. WR321 did not prevent the entry of HIV-1
into MDM. However, once WR321 was internalized along with HIV-1 the mAb acted intracellulary to
prevent the release of virions from MDM and also triggered the release of b-chemokines.
Published by Elsevier Inc.Introduction
The search for an immunizing formulation that can induce
broadly neutralizing antibodies against HIV-1 has proved to be
challenging especially in view of the discovery that the broadly
neutralizing human monoclonal antibodies (mAbs) 2F5 and 4E10,
in addition to their speciﬁcity for protein epitopes in gp41 exhibit
very broad lipid binding speciﬁcities. These mAbs bind to cardi-
olipin, phospholipids, cholesterol, glycosphingolipids, squalene,
and lipid A (Haynes et al., 2005; Matyas et al., 2009b). There is
strong evidence for the participation of the viral membrane in the
neutralization process by the mAbs 2F5 and 4E10 (Alam et al.,
2009) and recent studies show that binding of the antibodies to
lipids could be part of the neutralizing mechanism (Haynes et al.,
2005; Matyas et al., 2009b; Alving et al., 2006; Sanchez-Martinez




blood mononuclear cells; PI,
sphate; PIP2,importance of lipids in binding and neutralization of HIV-1 with a
panel of lipid-speciﬁc murine monoclonal antibodies. In those
studies, murine IgM mAbs (WR301 and WR304) that exhibit only
lipid binding activity and do not bind to recombinant gp120 or
gp41 neutralized HIV-1 infection in the PBMC assay (Brown et al.,
2007; Matyas et al., 2009b). The ability of anti-lipid antibodies to
neutralize HIV-1 infection in the PBMC assay has also been
demonstrated with several b2-glycoprotein 1-independent anti-
phospholipid human IgG mAbs (PGN632, P1, IS-4, and CL1).
(Moody et al., 2008, 2010). These observations are pertinent since
it is well known that retroviruses including HIV-1 acquire their
lipids during budding from the plasma membrane of a host cell
(Nguyen and Hildreth, 2000).
In addition to WR301 and WR304, several other murine IgM
and IgG mAbs have been generated in our laboratory and
extensively characterized for their protein and lipid binding
properties (Beck et al., 2008; Karasavvas et al., 2008). WR321 is
a murine IgG mAb with exquisite speciﬁcity for phosphoinositides
phosphatidylinositol-4-phosphate (PIP) and phosphatidylinositol-
4,5-bisphosphate (PIP2) (Matyas et al., 2010). Phosphoinositides
that are recognized by WR321 do not exist on the external surface
of cells. However, they are exclusively present on the cytoplasmic
leaﬂet of the plasma membrane (Di Paolo and De Camilli, 2006).
Plasma membrane associated PIP2 has been shown to be crucial
for HIV-1 viral assembly, in particular for the assembly of Gag
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tious virus production (Chan et al., 2008; Ono et al., 2004). In the
present study, we have examined the mechanism of neutraliza-
tion of HIV-1 by WR321 using a pure and deﬁned subset of
PBMCs, namely human monocyte-derived macrophages (MDM).
WR321 was internalized after it bound to HIV-1. WR321 exerted
its effect from within the cell by preventing the release of HIV-1
and by inducing the secretion of b chemokines.Results
Characterization of in vitro generated human monocyte-derived
macrophages (MDM)
Monocytes were isolated from PBMCs of HIV-1 seronegative
donors using a cold agglutination procedure and cultured in vitro
for 7 days. To ascertain that the in vitro differentiated cells were
indeed MDM, cells were harvested and analyzed for the expres-
sion of various cell surface molecules by ﬂow cytometry. As
shown in Fig. 1, the cells were CD14þ , CD11cþ , CD11bþ , CD3 ,
CD20 , CD40 , and CD80 . The cells expressed high levels of
class I (HLA-A, B, C) and class II (HLA-DR) molecules and low
levels of CD4 and CD86 molecules on their cell surface. The cells
expressed high levels of CD32 (FcgRII) and CD16 (FcgRIII), and
were also positive for CD64 (FcgRI) and CD195. Phenotypic
analyses showed that the cells were not T cells or B cells but
expressed markers indicative of MDM.
In vitro infection of primary MDM with US-1 virus
MDM were infected with US-1 as described below. Cells were
then washed and cultured for varying periods of time. Three
different read-outs were utilized to determine the level of infection
of MDM: (i) ﬂow cytometry for the detection of intracellular HIV-1
p24 antigen in the infected MDM (Fig. 2A); (ii) ELISA for the
quantitation of HIV-1 p24 antigen in the supernatants from
the infected cultures (Fig. 2B) and (iii) electron microscopy forFig. 1. Phenotypic analyses of MDM. Monocytes were isolated from PBMCs of an HIV-1 s
were harvested on day 7 post in vitro culture, stained with a cocktail of mAbs, and anal
represent staining of different cell surface molecules (unﬁlled) and isotype controls (ﬁthe intracellular detection of HIV-1 virions in infected MDM
(Fig. 2C–E).
Following in vitro culture of infected MDM, there was a gradual
increase in the percentage of MDM that were positive for HIV-1
p24 antigen by ﬂow cytometry compared to uninfected MDM
(Fig. 2A). A representative experiment with the percentage of
infected cells in each of the panels is shown. At day 3 post-
infection, the percentage (mean7S.D.) of infected MDM from
three independent experiments was 5.6070.91%. This number
increased signiﬁcantly over time. The percentage of infected
MDM was 14.3073.78% (p¼0.01), 27.9777.12% (p¼0.005),
and 44.0374.58% (p¼0.0001), respectively on days 5, 7, and
9 post-infection. There was a concomitant increase in the amount
of p24 present in the culture supernatants of these cells (Fig. 2B).
The concentration of HIV-1 p24 antigen in the corresponding
culture supernatants increased signiﬁcantly (pr0.04) on days 3,
5, 7, and 9 post-culture compared to uninfected cultures (Fig. 2B).
Numerous mature HIV-1 virions and virions at various stages of
budding were detected inside intracytoplasmic vacuoles of HIV-1-
infected MDM on day 10 post-infection (Fig. 2C–E) indicating a
productive infection.
Neutralization of HIV-1 infection of MDM by mAbs
The lipid speciﬁcities of WR321 are shown in Table 1. In the
initial experiments, MDM differentiated from a single HIV-1
seronegative donor were used to evaluate the ability of WR321
to neutralize US-1 virus infection. The human IgG mAbs, 2F5
(speciﬁc for both HIV-1 envelope protein and lipids), and CL-1
(speciﬁc for lipids), were used as control mAbs.
Two separate neutralization assay formats, preincubation of
WR321 with MDM (cell format) and preincubation of WR321
with HIV-1 (virus format) were utilized. In the cell format (Fig. 3),
MDM were preincubated with WR321 before infection with
puriﬁed US-1 virus as described in the Materials and methods
section. The mAb were tested in triplicate at a ﬁnal concentration
of 10 mg/ml and neutralization of the virus above 50% was
considered positive. The human IgG mAbs, 2F5 and CL1, wereeronegative donor and differentiated into MDM following in vitro culture. The cells
yzed by ﬂow cytometry for the expression of cell surface markers. Histogram plots
lled). A representative experiment of several independent experiments is shown.
Fig. 2. HIV-1 infection of MDM. MDM were infected in vitro with puriﬁed US-1 virus (8 ng of p24) on day 7 of culture as described in the Materials and methods section.
Cells and culture supernatants were harvested at the indicated time-points. Cells were stained and analyzed for the presence of intracellular p24 by ﬂow cytometry. (A)
Panels show dot plots of uninfected and US-1-infected MDM cultures at 5, 7, and 9 day post-infection. (B) The supernatants from these cells (infected MDM represented by
closed circles and uninfected MDM represented by open circles) were collected at the indicated time-points and analyzed in triplicate for p24 levels by ELISA. (C)–(E)
electron micrographs of MDM infected with US-1 at day 10 post-infection (C and D). HIV-1 can be seen budding (indicated by arrowheads) on the membrane of a vacuole
(C) with budding nearing completion in (D). Bar¼200 nm, respectively. (E) Arrows denote numerous US-1 virions inside a vacuole (Bar¼500 nm). A representative of two
separate experiments is shown.
Table 1
Binding speciﬁcities and endotoxin concentration for murine and human monoclonal antibodies. The endotoxin concentration in the murine and human mAb preparations
was measured by using a commercially available limulus amoebocyte lysate (LAL) kinetic chromogenic assay kit (Kinetic-QCL) and the endotoxin units (EU) were
calculated. The lipid and protein binding speciﬁcities were previously determined.
Lipid and protein binding speciﬁcities* Endotoxin concentration
mAb PIP PIP2 PI Cholesterol GalCer Lipid A MPER gp41 gp120 pg/10 mg EU/10 mg
WR321 (IgG) þ þ        0.012 0.166
CL1 (IgG) þ þ þ þ      0.005 0.069
2F5 (IgG)       þ þ  0.005 0.068
þ: binding; : no binding.
n Binding as previously determined (Alving et al., 1987; Matyas et al., 2009b, 2010).
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of preincubation with mAbs served as the infection control.
At day 5 post-infection, the percentage (mean7S.D.) of MDM
infected in the absence of mAbs (Media, Infection control) was
15.1773.26% (Fig. 3A, panel 2). When compared to the infection
control, preincubation of MDM with 2F5 resulted in complete
neutralization of intracellular US-1 virus infection (Fig. 3A, panel
3), whereas preincubation with CL1 neutralized the infection by
61.3173.89% (Fig. 3A, panel 4). Based on the measurement of
intracellular and extracellular p24, there was a concomitant and
signiﬁcant decrease in the amounts of p24 in infected MDM
preincubated with mAbs 2F5 and CL1 compared to the infection
control indicating neutralization of the virus (Fig. 3B). In contrast,
virus infection was not neutralized when MDMwere preincubated
with WR321 based both on the % of intracellular p24 (Fig. 3A,
panel 5) and on the amount of intracellular and extracellular p24
compared to cells incubated with the virus alone (Fig. 3B).
In the virus format (Fig. 4), puriﬁed US-1 virus was preincu-
bated separately with each of the mAbs. MDM infected with virus
alone, served as the infection control (Media, Fig. 4A, panel 2). 2F5
and CL1 neutralized HIV-1 infection by 100% and 80.9274.12%,
respectively (po0.0001) based on intracellular p24 (Fig.4A,panels 3 and 4) and measurement of both intracellular and
extracellular p24 (Fig. 4B); whereas WR321 neutralized US-1
infection by 58.3773.54% based on intracellular p24 as measured
by ﬂow cytometry (Fig. 4A, panel 5) and ELISA (Fig. 4B). However,
based on the amount of extracellular p24 (Fig. 4B), WR321
signiﬁcantly neutralized the virus to 87% (p¼0.005).
Binding of WR321 to HIV-1
The results of the virus neutralization assay format (Fig. 4)
suggested that WR321 neutralized HIV-1 by binding to the virus.
To conclusively demonstrate this, we utilized electron microscopy
to visualize the binding of WR321 to US-1. Binding of WR321 to
US-1 (Fig. 5A) was conﬁrmed by the binding of the anti-IgG
labeled-gold particles while the negative control IgG mAb, TFTB
did not exhibit binding of the gold particles to US-1 (Fig. 5B).
The effect of donor variability and HIV-1 subtypes on the neutralizing
effects of WR321
To further demonstrate that neutralization of HIV-1 by WR321
was not restricted to US-1 or to a particular donor, MDM
Fig. 3. Effect of preincubation of MDM with murine mAb WR321 on US-1 infection. MDM were preincubated with human IgG mAbs (2F5, CL1; panels 3 and 4) or murine
IgG mAb (WR321, panel 5) for 1 h at 37 oC/5% CO2. All mAbs were used at a ﬁnal concentration of 10 mg/ml. Cells were washed and infected in triplicate with puriﬁed US-1
(8 ng). Cells preincubated with media (panel 1) and infected with US-1 served as the infection control (panel 2). Cells and culture supernatants were harvested on day
5 post-infection. Intracellular and extracellular p24 in MDM and culture supernatants were evaluated by ﬂow cytometry and ELISA, respectively. (A) Dot plots show the
percentages of MDM positive for intracellular p24. A representative of triplicate infections is shown. (B) Bar graph represents the % neutralization (mean7S.D.) of HIV-1
infection by the different mAbs compared to the infection control based on the measurement of extracellular (open bars) and intracellular p24 (ﬁlled bars). Each of the
samples from triplicate cultures was analyzed in duplicate. A representative of three independent experiments is shown.
Fig. 4. Effect of preincubation of US-1 with murine mAb WR321. MDM were infected in triplicate with puriﬁed US-1 (8 ng of p24) that was previously preincubated with
10 mg/ml of human IgG mAb (2F5, CL1) or murine IgG mAb (WR321) for 1 h at 37 1C/5% CO2. MDM infected with US-1 in the absence of mAbs served as the infection
control. Cells and culture supernatants were harvested on day 5 post-infection. Intracellular and extracellular p24 in MDM and culture supernatants were evaluated by
ﬂow cytometry and ELISA, respectively. (A) Dot plots show the percentages of MDM positive for intracellular p24. A representative of triplicate infections is shown. (B) Bar
graph represents the % neutralization (mean7S.D) of HIV-1 infection by the different mAbs compared to the infection control based on the measurement of extracellular
(open bars) and intracellular (ﬁlled bars) p24. Each of the samples from triplicate cultures was analyzed in duplicate. A representative of three independent experiments is
shown. Neutralization that is signiﬁcant based on extracellular p24 measurement compared to intracellular p24 measurement is represented by an n (p¼0.001).
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(#032, #124, #202) and two additional primary viruses, BaL
(clade B) and MO66 (clade A/E) were utilized along with 2F5
and CL1 as the control mAbs (Table 2; Fig. 6). All infections weredone in triplicate and the neutralizing effect of the three mAbs on
the three virus subtypes was determined on day 5 post-infection.
MDM infected with the respective puriﬁed virus subtypes in the
absence of mAbs served as the infection control.
Fig. 5. Visualization of binding of WR321 to HIV-1. Monoclonal antibodies WR321 (panel A) and TFTB (panel B) were preincubated with puriﬁed US-1 virus for 16 h at 4 1C
in duplicate. The virus-mAb mixtures were placed on formar-coated copper grids followed by gold labeled-goat anti-mouse IgG antibody (10 nm gold particles) as
described in the Materials and methods section. The grids were washed, stained with 1% phosphotungstic acid, and examined under a Phillips CM100 Transmission
Electron Microscope. Numerous gold particles can be seen attached to US-1 preincubated with WR321 (panel A) compared to US-1 preincubated with TFTB-1 (control
antibody, panel B). Two independent experiments were carried out and in each case approximately 15 ﬁelds were examined. A representative ﬁeld is shown
(Bar¼100 nm).
Table 2
Infectivity of MDM from different donors with different HIV-1 subtypes. MDM
were prepared from three seronegative donors and infected in vitro in triplicate
with HIV-1 subtypes (US-1, BaL, and MO66). Cells were harvested on day 5 post-
infection and evaluated for the presence of intracellular p24 by ﬂow cytometry.
These experiments were performed twice. Data are expressed as % of p24 positive
cells (Mean7S.D.).
Percentage of p24-positive MDM (Mean7S.D.)
Donor US-1 (Clade B) BaL (Clade B) MO66 (Clade CRF01_AE)
#032 23.1372.98 43.3474.87 12.5171.51
#124 30.7972.88 31.7974.02 22.3473.48
#202 5.6670.71 28.5572.42 12.5772.41
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different degrees of susceptibility to infection with the different
HIV-1 subtypes. The variability in HIV-1 susceptibility among the
three different donors is not surprising since the capacity of MDM
to sustain viral replication varies between individuals probably
due to certain host or innate factors that could limit several steps
of the viral life-cycle from viral entry to virus release (Eisert et al.,
2001).
WR321 did not neutralize any of the three viruses tested in
any of the three donor MDM tested (Fig. 6A–C) when the mAb
was preincubated with MDM (cell format). Neutralization as
determined by the amount of extracellular or intracellular p24
in all cases based on the infection control was well below the 50%
cut off. In contrast, 100% neutralization was consistently obtained
with the mAb 2F5 for all three viruses in all three donor MDM,
while 70% to 80% neutralization was obtained with the mAb CL1
when it was used either in the cell (Fig. 6A–C) or the virus format
(Fig. 6D–F).
Pre-incubation of WR321 with all three viruses resulted in 60%
to 80% neutralization with MDM from all three donors with a
signiﬁcantly higher degree of neutralization of all three viruses
based on the measurement of extracellular p24 compared to the
measurement of intracellular p24 (Fig. 6D–F). There were no
signiﬁcant differences in neutralization of any of the viruses
tested with the control mAbs 2F5 and CL1 based on the measure-
ment of intracellular or extracellular p24.
Internalization of WR321 and chemokine production
To conclusively prove that the virus-WR321 complex was
internalized, MDM were incubated with media, WR321, US-1, or
US-1 pre-incubated with WR321 as described in Materials and
methods Section and then analyzed for the presence of intracel-
lular p24 and intracellular WR321 by ﬂow cytometry. As shown in
the histograms (Fig. 7A) and Table 3, a shift in the meanﬂuorescent intensity (MFI) of the cells was observed only when
MDM were treated with WR321 preincubated with US-1. The MFI
of cells that showed WR321 staining was 3-fold higher when
MDM were cultured with HIV-1 preincubated with the mAb
WR321 compared to MDM exposed to HIV-1 alone, WR321 alone,
or to ﬂuorescently labeled secondary antibody alone that was
added after the cells were ﬁxed and permeabilized. The level of
infection of the cells under these same conditions was measured
by staining for intracellular p24. The amount of p24 present in the
cells at 36 h was low; nonetheless a slight shift in the MFI for p24
staining was only seen in cells incubated with virus alone or with
virus preincubated with WR321 (data not shown). These results
indicate that WR321 is internalized only when it is bound to the
virus and not in the absence of the virus.
Supernatants from MDM cultured under the four experimental
conditions described above were assayed for the presence of
chemokines MIP-1a (Fig. 7B) and MIP-1b (Fig. 7C). MDM cultured
with media alone produced little or no chemokines. WR321 had
extremely low levels of endotoxin (Table 1) and incubation of
MDM with the mAb alone induced very low amounts of MIP-1a
and MIP-1b. Slightly higher amounts of both chemokines were
induced with virus alone. As predicted, chemokine production
was signiﬁcantly higher in the MDM cultures containing virus
preincubated with WR321. A similar pattern of chemokine
production was seen in culture supernatants collected after 5
days of culture under the four experimental conditions described
above (data not shown).Discussion
The primary targets of HIV-1 are CD4þ T cells and macro-
phages. In addition to their highly phagocytic nature, macro-
phages are professional antigen presenting cells, one of the ﬁrst
responders at the site of an infection, secrete a number of
different cytokines and chemokines, and serve as a bridge
between the innate and adaptive immune systems. Because of
their long half-life of several months and their relative resistance
to the cytopathic effects, tissue macrophages can harbor HIV-1 for
extensive periods of time producing large amounts of virions
(Carter and Ehrlich, 2008).
In primary CD4þ T cells, cellular entry of HIV-1 requires a
fusion event between the cellular membrane and the viral lipid
envelope while HIV-1 assembly and release occurs at the plasma
membrane involving lipid rafts (Nguyen and Hildreth, 2000). In
contrast, the mode of entry and exit of HIV-1 in primary human
macrophages is not very clear. In these cells, fusion and endocy-
tosis, macropinocytosis, and involvement of Fc receptors
(Miyauchi et al., 2009; Marechal et al., 2001) have all been
Fig. 6. Neutralization of HIV-1 infection by mAbs. The ability of murine mAb WR321 to neutralize HIV-1 infection (US-1, BaL, MO66) was assayed with MDM prepared
from three seronegative donors (#032, #124, #202) under the two experimental conditions (cell format and virus format). In the cell format (panels (A)–(C)), triplicate
wells of MDM were preincubated with mAb for 1 h washed, and subsequently infected with three HIV-1 subtypes. In the virus format (panels (D)–(F)), the three HIV-1
subtypes were preincubated with mAb for 1 h and subsequently added to triplicate wells of MDM. 2F5 and CL1 were used as control mAbs. MDM infected with the HIV-1
subtypes in the absence of mAb served as the infection control. HIV-1 subtypes were used at 8 ng in all the infections. All mAbs were used at a ﬁnal concentration of 10 mg/
ml. Cells were harvested on day 5 post-infection and analyzed for the presence of intracellular p24 by ﬂow cytometry. (A)–(C) Bar graphs show the % neutralization of HIV-
1 infection of MDM in the cell format. (D)–(F) Bar graphs show the % neutralization of HIV-1 infection of MDM in the virus format. Values shown are the mean7standard
deviation of triplicate samples. Percent neutralization (mean7S.D) of HIV-1 infection by the different mAbs compared to the infection control is based on the
measurement of extracellular and intracellular p24. A representative experiment of three independent experiments is shown. Signiﬁcant differences in neutralization of
intracellular versus extracellular p24 by WR321 mAb are represented by an n (n, p¼0.03; nn, p¼0.007).
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plasma membrane have been demonstrated as the sites of HIV-1
assembly and budding (Deneka et al., 2007; Welsch et al., 2007).
However, it is clear that both cholesterol and lipid rafts are
important for virus entry and for budding irrespective of the cell
type (Carter et al., 2009). Retroviruses, including HIV, acquire
their lipid coats by budding through host plasma membranes
(Brugger et al., 2006; Nguyen and Hildreth, 2000). A comprehen-
sive mass spectrometry analysis of the lipid content of HIV-1
demonstrated that it was enriched in cholesterol, ceramide,
ganglioside GM3, PIP, and PIP2 (Chan et al., 2008). Clearly, lipids
are important in HIV-1 infection and generation of antibodies
against lipids may be important for neutralization of HIV-1
infection in susceptible target cells.
In the current study, we investigated the inhibition of HIV-1
infection by WR321 and the mechanism of neutralization. For this
purpose, we set up a human MDM system as target cells for HIV-1
infection. Unlike, the macrophage single cycle infection utilized
by Holl et al., (2004), our MDM system consisted of multiple
rounds of infection. HIV-1 was neutralized only when WR321 was
preincubated with the virus and not when the mAb was pre-
incubated with MDM. Therefore, it is reasonable to assume thatthis outcome was due to WR321 binding to the virions. WR321
binds exclusively to PIP and PIP2. Phosphoinositides that are
recognized by WR321 do not exist on the external surface of cells,
but are present in relatively high concentrations on the inner
leaﬂet of the plasma membrane lipid bilayer (Di Paolo and De
Camilli, 2006) as well as on the surface of virions and largely
acquired during viral budding. Binding of WR321 to HIV-1 was
conclusively demonstrated by electron microscopy. In our study,
we have used a deﬁned MDM system which is not a mixture of
many different cell types as is the case with PBMCs and showed
that WR321 neutralized MDM infection by binding to the virions.
Furthermore, there was a signiﬁcant increase in both MIP-1a and
MIP-1b production only when MDM were cultured with WR321
that had been pre-incubated with HIV-1 compared to MDM
cultured just with WR321 or HIV-1.
It has been demonstrated that interference in the interaction
between HIV-1 Gag protein and PIP2 leads to defective non-
infectious particles (Chan et al., 2008; Ono et al., 2004). Our data
demonstrate that WR321 mediates its effect only when it is
bound to the virus and internalized by MDM. In addition to
triggering the release of chemokines, we hypothesize that WR321
because of its exclusive speciﬁcity to phosphoinositides binds to
Fig. 7. Internalization of WR321 and induction of b-chemokines. MDM were incubated with media, WR321, US-1, or WR321 preincubated with US-1 as described in
Materials and methods section. Cells and culture supernatants were harvested. Cells were ﬁxed, permeabilized, and stained with FITC-conjugated anti-mouse mAb. A
separate aliquot of ﬁxed and permeabilized MDM were stained with FITC-conjugated anti-mouse mAb as a control. The gray histogram represents unstained cells.
Histograms show the detection of WR321 staining in the MDM preparations as visualized by ﬂow cytometry (A). Culture supernatants were analyzed for MIP-1a and MIP-
1b by ELISA. Bar graphs show the concentration of MIP-1a (B) and MIP-1b (C). The mean7S.D. of triplicate samples is shown. Statistical signiﬁcance for amount of b-
chemokine production was assessed by Mann–Whitney t-test and the p values are indicated in the ﬁgure.
Table 3
Mean ﬂuorescence intensity (MFI) of WR321 staining. MDM were incubated with
media alone, WR321, US-1 alone, or WR321 preincubated with US-1 as described
in the Materials and methods section. Cells were harvested, ﬁxed, permeabilized,
and stained with FITC-conjugated anti-mouse mAb to visualize WR321 by ﬂow
cytometry. Data are expressed as mean ﬂuorescence intensity (MFI) of WR321





FITC conjugated anti-mouse alone 7.9
WR321 preincubated with virus 25.7
O. Jobe et al. / Virology 430 (2012) 110–119116PIP and prevents either the proper assembly or the budding of the
virions from MDM. This hypothesis is supported by the observed
differences seen in the neutralization of HIV-1 by WR321 based
on the measurement of intracellular and extracellular p24. A
signiﬁcantly greater degree of neutralization was observed based
on the amount of extracellular p24 (87% neutralization) measured
compared to intracellular p24 (58% neutralization, Fig. 4B). These
results would suggest that HIV-1 virions are probably contained
within the cell and are prevented from exiting the cell thereby
leading to lower amounts of p24 in the culture supernatant
compared to infection control resulting in the observed greater
neutralization. Such a difference in inhibition of HIV-1 infection
based on the intracellular and extracellular p24 measurement
O. Jobe et al. / Virology 430 (2012) 110–119 117was not observed with the mAb 2F5 since its mechanism of action
is at the entry stage. To the best of our knowledge, WR321 is
unique in this aspect and probably the ﬁrst anti-phosphoinositide
mAb to exert its effects from within the cell by preventing the
release of virions and also triggering the release of chemokines.
The chemokines would then bind to the chemokine receptor CCR5
and inhibit the binding of virions.
A major goal in the area of HIV-1 research is to induce the
production of broadly cross-neutralizing antibodies. However,
immunization strategies aimed at generating these types of
antibodies with broad neutralizing capabilities have so far been
futile largely due to the lack of understanding of the mechanism
of production of these antibodies (Montero et al., 2008; Phogat
et al., 2008). Furthermore, it is important to realize that in vivo the
virus encounters several different cell types and the methods of
viral entry are varied. Thus, it is important to not only develop
antibodies that are not restricted in their inhibition to one cell
type and would work with all hematopoietic cells, but utilize
several different assays systems to measure neutralization.
WR321 not only neutralizes HIV-1 in a macrophage system by
preventing the proper assembly and release of the virions and by
the induction of chemokines, but also neutralizes HIV-1 in a
PBMC neutralization assay as was previously shown (Matyas
et al., 2010). Therefore, several different assay systems should
be utilized to screen antibodies generated by potential candidate
vaccine formulations before drawing major conclusions about
their feasibility in clinical trials.Materials and methods
Antibodies and reagents
Monoclonal antibodies anti-CD3-FITC, CD4-PE, HLA-A, B,
C-FITC, CD4-FITC, CD40-FITC, CD11c-PE, CD11b-PE, CD195-PE,
CD80-PE, CD64-PE, CD184-PE, CD14-PerCP, CD20-APC, CD56-
APC, HLA-DR-APC, CD86-APC, and CD1a-APC, were obtained from
BD Pharmingen. Anti-p24-FITC and anti-p24-PE were purchased
from Beckman Coulter. WR321 (murine IgG) was generated in our
laboratory (Matyas et al., 2010, 2009b; Wassef et al., 1984). CL1, a
human mAb derived from a patient with systemic lupus erythe-
matosus, with speciﬁcity for cardiolipin, phosphoinositides, cho-
lesterol, and sulfatide (Moody et al., 2008; Matyas et al., 2009a,
2010), was provided by Dr. Barton Haynes (Duke University
Medical Center, Durham, NC). Anti-gp41 MPER mAb 2F5 was
purchased from Polymun Scientiﬁc Immunbiologische Forschung
GmbH. TFTB, a mouse IgG mAb to the ricin B chain was puriﬁed as
previously described (Matyas et al., 2010) and was used as a
negative control antibody. Polybrene was purchased from Sigma-
Aldrich and formar-coated 300 mesh copper grids were obtained
from Electron Microscopy Sciences.
Endotoxin detection
Endotoxin levels in WR321, 2F5, and CL1 were measured by
using a commercially available limulus amoebocyte lysate (LAL)
kinetic chromogenic assay kit (Kinetic-QCL, Lonza). The assay was
carried out according to the manufacturer’s instructions. The lipid
and protein binding speciﬁcities of the murine and human mAbs
and their endotoxin levels are shown in Table 1.
Virus puriﬁcation
HIV-1 stocks of primary isolates of US-1 and BaL (clade B) and
MO66 (clade CRF01_AE) grown in PBMCs were provided by Dr.
Victoria Polonis (USMHRP). The supernatant containing the viruswas collected either on day 4 or on day 5, clariﬁed by centrifuga-
tion at 311 g for 10 min, and passed through a 0.22 mm ﬁlter.
The culture supernatant was subjected to ultracentrifugation at
100,000 g for 90 min at 4 1C and the virus pellet was resus-
pended in 400 ml of PBS. The virus was mixed with protein A/G
beads that had been pre-coated with anti-acetylcholinesterase
antibody (10 mg/20 ml of beads) and rotated for 60 min at 4 1C.
The mixture was centrifuged in a microcentrifuge at 16,110 g
for 1 min to pellet the beads. The supernatant was placed in a
clean tube and subjected to a second round of immunodepletion
to remove any contaminating exosomes present after the ﬁrst
round of depletion (Cantin et al., 2008). Anti-CD45 antibody
cocktail was then added to the supernatant for 15 min at RT
followed by the addition of magnetic nanoparticles (CD45 deple-
tion kit, StemCell Technologies, Vancouver, Canada) for 10 min at
RT to remove microsomes (Trubey et al., 2003). Samples were
placed on a magnet for 3–5 min and the supernatant was
removed. Virus samples were stored in liquid nitrogen until use
in aliquots containing 15% FBS that had been subjected to
ultracentrifugation to remove bovine exosomes. Infectivity and
p24 concentration were determined before and after puriﬁcation
to ensure that infectivity was not lost during the puriﬁcation
procedure.
Preparation of human monocyte-derived macrophages (MDM)
For the generation of MDM, PBMCs from healthy volunteers
were collected under an internal review board (IRB)-approved
protocol, RV229/WRAIR number 1386. Monocytes were isolated
from peripheral blood mononuclear cells (PBMCs) of HIV-1
seronegative donors using the cold agglutination procedure
(Mentzer et al., 1986). Brieﬂy, 50106 PBMCs were resuspended
in 1.2 ml cold monocyte media (RPMI supplemented with 10%
heat-inactivated FBS, 1% L-glutamine plus 1% penicillin/strepto-
mycin) in a 15 ml centrifuge tube and slowly rotated horizontally
for 45 min at 4 1C. The tube was placed vertically on ice for 30 min
and then 1.5 ml of cold FBS was slowly dispensed under the cell
pellet. Following aspiration of the media and FBS, the cell pellet
was resuspended in 10 ml monocyte media and spun at 311 g
for 10 min at 4 1C. The cell pellet was resuspended in macrophage
media [monocyte media supplemented with 50 ng/ml macro-
phage colony stimulating factor (M-CSF)]. Cell viability as deter-
mined by trypan blue exclusion was 499%. The purity of the
monocytes (490%) was determined by staining with anti-CD14
and anti-CD11b mAbs and analyzed by ﬂow cytometry (FACSCa-
libur, BD Biosciences). Monocytes were cultured in 24-well plates
at a concentration of 1106 cells/well. The culture media was
changed every two days and MDM were used at day 7 post-
culture.
Flow cytometry
Brieﬂy, monocytes or MDM (1106 cells/ml) were resus-
pended in cold FACS buffer (PBS-containing 0.5% BSA) and
incubated with 5 to 10 mg of the relevant mAbs directed against
cell surface molecules for 20 min at 4 1C. Cells were washed in
FACS buffer and ﬁxed in PBS-containing 2% paraformaldehyde.
Flow cytometry was performed on a FACSCalibur. Data was
analyzed using FlowJo 8.8.6 software (TreeStar Inc.).
In order to determine if WR321 binds to MDM, cells
(0.5–1106 cells/ml) were washed in FACS buffer and resus-
pended in 100 ml blocking buffer (PBS-containing 20% normal
goat serum) for 90 min at 4 1C. For evaluation of extracellular
binding, WR321 mAb (10–50 mg/ml) was then added to the cells
in the presence of anti-CD14 mAb and the cells were incubated
for an additional 60 min at 4 1C. Following two washes in FACS
O. Jobe et al. / Virology 430 (2012) 110–119118buffer, the cells were resuspended in 100 ml FACS buffer contain-
ing 5 mg of goat anti-mouse FITC secondary Ab. Cells were then
incubated for 45 min at 4 1C. Cells were washed in FACS buffer
and ﬁxed in PBS-containing 2% paraformaldehyde. Flow cytome-
try and data analyses were performed as mentioned above.
Electron microscopy
MDM were infected with puriﬁed US-1 virus (see above). Cells
were collected on day 10 post-infection, washed, and then
incubated with ﬁxative (PBS-containing 4% formaldehyde and
1% glutaraldehyde) for 1 h at RT followed by overnight incubation
at 4 1C. Following washing with phosphate buffer, the cells were
post-ﬁxed in 1% osmium tetroxide, dehydrated in graded ethanol
and embedded in Embed 812 resin (Electron Microscopy
Sciences). Thin sections (80–100 nm) were cut, stained with lead
citrate and uranyl acetate and examined using a LEO 912 Electron
microscope (Carl Zeiss SMT).
In order to determine the binding of WR321 to HIV-1, the mAb
was preincubated with puriﬁed US-1 virus at a ﬁnal concentration
of 10 mg/ml for 16 h at 4 1C. TFTB (10 mg/ml) served as a negative
control. The virus-mAb mixture was placed on formar-coated
300-mesh copper grids that were previously coated with poly-
brene (5 mg/ml). Following incubation at RT for 5 min, the grids
were blocked, with 4% goat sera in PBS for 10 min. Goat anti-
mouse IgG antibody labeled with 10 nm gold particles (Electron
Microscopy Sciences) was added and the grids were incubated for
60 min at RT. The grids were gently washed in PBS and incubated
in ﬁxative (PBS-containing 4% formaldehyde and 1% glutaralde-
hyde) for 20 min at RT. The grids were washed, stained with 1%
phosphotungstic acid, and examined under a Phillips CM100
Transmission Electron Microscope (FEI).
HIV-1 infection of MDM and measurement of intracellular p24
All incubations containing MDM in this experiment and sub-
sequent experiments were carried out at 37 1C/5%CO2. MDM
(1106) grown in 24-well plates were incubated with 500 ml of
fresh infection media (macrophage media-containing 2 mg/ml
polybrene) for 1 h. The media was aspirated, 300 ml of infection
media containing puriﬁed US-1, BaL, or M066 virus (8 ng of p24)
was added to the wells. The plate was centrifuged at 863 g for
1 h at 37 1C to allow the virus to gain better access to the cells,
and then incubated for 4 h. The virus suspension was then
aspirated, cells were extensively rinsed with monocyte media
containing 2 mg/ml polybrene to remove unbound virus, and the
plate was incubated in 1 ml of fresh infection media for 5 days.
For detection of HIV-1-infected macrophages (CD14þ p24þ
cells), MDM were harvested, washed, and incubated in FACS
buffer containing 5–10 mg of anti-CD14 mAb for 20 min at 4 1C.
Following washing in FACS buffer, the cells were ﬁxed and
permeabilized according to the manufacturer’s instructions (Cal-
tag), and then stained with anti-p24-FITC (Beckman Coulter) or
with anti-p24-PE for 15 min at RT. Uninfected cells stained with
anti-p24-FITC or anti-p24-PE as well as infected cells stained with
FITC- or PE-conjugated IgG1 served as the controls. Cells were
washed in FACS buffer, resuspended in PBS and evaluated by ﬂow
cytometry using a FACSCalibur. Data was analyzed using FlowJo
8.8.6 software and the % of cells positive for intracellular p24 was
calculated.
Measurement of extracellular p24
Supernatants harvested from HIV-1 infected MDM cultures
were assayed in triplicate for the presence of p24, by an ELISAaccording to the manufacturer’s instructions using a HIV-1 p24
antigen capture assay kit (Advanced BioScience Laboratories).
Antibody neutralization assays
Two separate formats, cell format (A) and virus format
(B) were utilized. In the cell format, WR321 was preincubated
with MDM. In the virus format, WR321 was preincubated with
the virus.A) Cell format: To determine whether WR321 could bind to MDM
and neutralize HIV-1 infection, MDM (1106 cells/well in 24-
well plates) were preincubated with the mAb at for 1 h. The
ﬁnal mAb concentration in the mixture in each case was
10 mg/ml. Pooled human sera from HIV-1 negative individuals
and mAb 2F5 served as the negative and positive controls,
respectively. After aspiration of the unbound mAb, the cells
were rinsed and 300 ml of infection media containing puriﬁed
US-1, BaL, or MO66 was then added to the wells, and the plate
was centrifuged at 863 g for 1 h at 37 1C. The plate was then
incubated for 4 h. Following aspiration of the virus suspension,
the cells were extensively rinsed, 1 ml of fresh infection media
was added, and the plate was incubated for 5 days. MDM and
culture supernatants were harvested and analyzed respec-
tively for the presence of intracellular and extracellular p24.B) Virus format: To determine whether WR321 could bind to
different virus isolates and neutralize infection of MDM, the
mAb was preincubated with puriﬁed US-1, BaL, or MO66 (8 ng
of p24). The ﬁnal mAb concentration in the mixture in each
case was 10 mg/ml. The positive and negative controls were
the same as that used for the cell format. Following incubation
for 1 h, the virus-mAb mixture was spun in a microfuge at
16,110 g for 30 min. The supernatants were aspirated
to remove the unbound mAbs. The individual virus pellets
were resuspended in 300 ml of infection media and added to
the respective wells of a 24-well plate containing MDM
(1106/well). Following centrifugation at 863 g for 1 h at
37 1C, the plate was further incubated for 4 h. After aspiration
of the virus suspension, cells were extensively rinsed and
incubated in 1 ml of fresh infection media for 5 days. MDM
and culture supernatants were harvested and analyzed respec-
tively for the presence of intracellular and extracellular p24. It
was determined in separate experiments that pelleted virus in
the absence of mAbs exhibited the same level of infectivity as
the unpelleted virus (data not shown). In both the cell and
virus formats, the % of neutralization was calculated based on
the amount of p24 in the presence and in the absence of
the mAbs.Internalization of WR321 and measurement of b-chemokines
WR321 (10 mg/ml) was preincubated with US-1 (8 ng of p24)
for 1 h at 37 1C/5% CO2 and the mixture added to wells of a
24-well plate containing MDM (1106 cells/well). Media alone,
media-containing WR321, or US-1 alone was added to corre-
sponding wells of MDM. The plate was centrifuged at 863 g for
1 h at 37 1C and further incubated for 36 h after which the cells
and culture supernatants were harvested. Cells were washed with
FACS buffer and stained with CD14 mAb. Following washing, the
cells were ﬁxed and permeabilized (Caltag), according to the
manufacturer’s instructions. The cells were stained for 1 h at RT
either with anti-p24-PE or with goat anti-mouse-FITC secondary
mAb in permeabilization buffer to visualize for the presence of
HIV-1 or WR321. The cells were washed in FACS buffer,
O. Jobe et al. / Virology 430 (2012) 110–119 119resuspended in PBS and evaluated by ﬂow cytometry using a
FACSCalibur.
Supernatants harvested from MDM cultures were assayed in
triplicate for the presence of MIP-1a and MIP-1b by ELISA
according to the manufacturer’s instructions using the respective
chemokine ELISA kits (R & D Systems).
Statistical analyses
Data are presented as the mean7S.D., and the statistical
differences among groups were analyzed by the Mann–Whitney
U test using Graphpad Prism 5.0 software.Acknowledgment and disclaimer
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